---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003998"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:12:30.185256+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Apellis reports preliminary Q4 2023 U.S. net product revenue of $138M, full year $366M

## Summary
- Q4 2023 U.S. net product revenue ~$138M: SYFOVRE $114M, EMPAVELI $24M.
- Full year 2023 U.S. net product revenue ~$366M: SYFOVRE $275M, EMPAVELI $91M.
- SYFOVRE: ~62,000 doses in Q4, ~160,000 total in 2023; ~95% of GA patients use SYFOVRE.
- EMPAVELI: 97% compliance; >50% existing and >90% new patients use Injector since Oct approval.

## SEC filing metadata
- accession: 0001193125-24-003998
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/0001193125-24-003998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/d51181d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003998
- JSON: https://secwatch.observer/filing/0001193125-24-003998.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003998.txt

## Key facts
- Earnings Releases
  Apellis Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023
  - Result: preliminary results
  source text: Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues of approximately $138 million for the fourth quarter and approximately $366 million for the full year 2023 for SYFOVRE ® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration and for EMPAVELI ® (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/0001193125-24-003998-index.htm
- Earnings Releases
  Apellis Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023
  - Result: preliminary results
  source text: Approximately $114 million and $275 million expected in preliminary U.S. net product revenues in the fourth quarter and full year 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/0001193125-24-003998-index.htm
- Earnings Releases
  Apellis Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023
  - Result: preliminary results
  source text: Approximately $24 million and $91 million expected in preliminary U.S. net product revenues in the fourth quarter and full year 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/0001193125-24-003998-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.